Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

FDA advisory committee votes in favor of approval for Vioxx

April 21, 1999

FASEB presentation for PD-159879, an MMP inhibitor with potent antiinflammatory activity

April 21, 1999

New COX-2-selective agents from Abbott

April 21, 1999

Health Canada grants priority review status for rofecoxib

April 20, 1999

New inhibitors of VCAM-1 binding to its receptor patented by Roche

April 20, 1999

Phosphodiesterase inhibition contributes to the antiinflammatory activity of darbufelone

April 19, 1999

Wide series of cytokine production inhibitors reported by JT

April 19, 1999

Canadian approval obtained, launch imminent for Celebrex

April 16, 1999

Roche describes preparation and use of cell adhesion inhibitors for chronic inflammatory disorders

April 14, 1999

Amarillo begins phase III trial of interferon alfa for Sjogren's syndrome

April 14, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...